Effects of Low-Dose and Long-Term Treatment with Erythromycin on Interleukin-17 and Interleukin-23 in Peripheral Blood and Induced Sputum in Patients with Stable Chronic Obstructive Pulmonary Disease

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Tan, Caimei ^a   Huang, Huijuan ^a   Zhang, Jianquan ^a   He, Zhiyi ^a   Zhong, Xiaoning ^a   Bai, Jing ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ERYTHROMYCIN; INTERLEUKIN 17; INTERLEUKIN 23; PLACEBO; THEOPHYLLINE;

6 MINUTE WALK DISTANCE TEST; ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE CONTROL; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXYGEN THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFLAMMATION; RISK REDUCTION; SPUTUM; TREATMENT DURATION; BLOOD; CHEMISTRY; METABOLISM; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; WALKING;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROMYCIN; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; WALKING;

EID: 84965126081     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/4173962     Document Type: Article

References (26)

1. S. Moitra, A. B. Bhome, and B. B. Brashier, "Aclidinium bromide/ formoterol fixed-dose combination therapy for COPD: the evidence to date, " Drug Design, Development and Therapy, vol. 9, pp. 1989-1999, 2015.
2. N. Angelis, K. Porpodis, P. Zarogoulidis et al. , "Airway inflammation in chronic obstructive pulmonary disease, " Journal of Thoracic Disease, vol. 6, supplement 1, pp. S167-S172, 2014.
3. A. Di Stefano, G. Caramori, I. Gnemmi et al. , "T helper type 17-related cytokine expression is increased in the bronchialmucosa of stable chronic obstructive pulmonary disease patients, " Clinical and Experimental Immunology, vol. 157, no. 2, pp. 316-324, 2009.
4. O. J. Harrison, J. Foley, B. J. Bolognese, E. Long III, P. L. Podolin, and P. T. Walsh, "Airway infiltration of CD4+ CCR6+Th17 type cells associated with chronic cigarette smoke induced airspace enlargement, " Immunology Letters, vol. 121, no. 1, pp. 13-21, 2008.
5. M. Pelletier, L. Maggi, A. Micheletti et al. , "Evidence for a crosstalk between human neutrophils and Th17 cells, " Blood, vol. 115, no. 2, pp. 335-343, 2010.
6. J. F. Alcorn, C. R. Crowe, and J. K. Kolls, "TH17 cells in asthma and COPD, " Annual Review of Physiology, vol. 72, pp. 495-516, 2009.
7. P. J. Barnes, "Emerging pharmacotherapies for COPD, " Chest, vol. 134, no. 6, pp. 1278-1286, 2008.
8. T. A. R. Seemungal, T. M. A. Wilkinson, J. R. Hurst, W. R. Perera, R. J. Sapsford, and J. A. Wedzicha, "Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations, " American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 11, pp. 1139-1147, 2008.
9. Z.-Y. He, L.-M. Ou, J.-Q. Zhang et al. , "Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease, " Respiration, vol. 80, no. 6, pp. 445-452, 2010.
10. G. J. Criner, J. Bourbeau, R. L. Diekemper et al. , "Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline, " Chest, vol. 147, no. 4, pp. 894-942, 2015.
11. F. Blasi, D. Bonardi, S. Aliberti et al. , "Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy, " Pulmonary Pharmacology and Therapeutics, vol. 23, no. 3, pp. 200-207, 2010.
12. I. Basyigit, F. Yildiz, S. K. Ozkara, E. Yildirim, H. Boyaci, and A. Ilgazli, "The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data, " The Annals of Pharmacotherapy, vol. 38, pp. 1400-1405, 2004.
13. X. N. Zhong, J. Bai, H. Z. Shi, C. Wu, G. R. Liang, and Z. B. Feng, "An experimental study on airway inflammation and remodeling in a rat model of chronic bronchitis and emphysema, " Zhonghua Jie He He Hu Xi Za Zhi, vol. 26, no. 12, pp. 750-755, 2003.
14. J. V. Fahy, H. A. Boushey, S. C. Lazarus et al. , "Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study, " American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 6, pp. 1470-1475, 2001.
15. B. M. Saraiva-Romanholo, V. Barnabé, A. L. I. Carvalho, M. A. Martins, P. H. N. Saldiva, and M. D. P. T. Nunes, "Comparison of three methods for differential cell count in induced sputum, " Chest, vol. 124, no. 3, pp. 1060-1066, 2003.
16. T. Fujii, J.-I. Kadota, K. Kawakami et al. , "Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection, " Thorax, vol. 50, no. 12, pp. 1246-1252, 1995.
17. J. L. Simpson, H. Powell, M. J. Boyle, R. J. Scott, and P. G. Gibson, "Clarithromycin targets neutrophilic airway inflammation in refractory asthma, " American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 2, pp. 148-155, 2008.
18. P. M. Hansbro and A. G. Jarnicki, "Macrolides for macrophages in chronic obstructive pulmonary disease, " Respirology, vol. 17, no. 5, pp. 739-740, 2012.
19. S. Hodge, G. Hodge, H. Jersmann et al. , "Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease, " American Journal of Respiratory and Critical CareMedicine, vol. 178, no. 2, pp. 139-148, 2008.
20. Y. Chang, J. Nadigel, N. Boulais et al. , "CD8 positive T cells express IL-17 in patients with chronic obstructive pulmonary disease, " Respiratory Research, vol. 12, article 43, 2011.
21. M. Huber, S. Heink, H. Grothe et al. , "Th17-like developmental process leads to CD8+ Tc17 cells with reduced cytotoxic activity, " European Journal of Immunology, vol. 39, no. 7, pp. 1716-1725, 2009.
22. J. M. Kramer and S. L. Gaffen, "Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy, " Journal of Periodontology, vol. 78, no. 6, pp. 1083-1093, 2007.
23. D. Banerjee, D. Honeybourne, and O. A. Khair, "The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial, " Treatments in RespiratoryMedicine, vol. 3, no. 1, pp. 59-65, 2004.
24. S. Kudoh, T. Uetake, K. Hagiwara et al. , "Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis, " Japanese Journal ofThoracic Diseases, vol. 25, no. 6, pp. 632-642, 1987.
25. E. Fouka, E. Lamprianidou, K. Arvanitidis et al. , "Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients, " Lung, vol. 192, no. 6, pp. 849-855, 2014.
26. F. L. Ramos and G. J. Criner, "Use of long-term macrolide therapy in chronic obstructive pulmonary disease, " Current Opinion in PulmonaryMedicine, vol. 20, no. 2, pp. 153-158, 2014.